Takeda Pharmaceutical Company

PODD Drug Delivery Conference Announces 2023 Keynotes and Agenda

Retrieved on: 
Wednesday, July 12, 2023
Teva Pharmaceuticals, Computational biology, GSK, Amgen, Gilead Sciences, Associate Director of National Intelligence and Chief Information Officer, Senior, Takeda, Administration, Chiesi Farmaceutici, Roche, Gene editing, Copley Place, Bristol Myers Squibb, Medicine, Research, MIT, Strategic Innovation Fund, Brain, CNS, AstraZeneca, PNS, AAV, Beam Therapeutics, Rare, Digital technology, Eli Lilly and Company, Novartis, Patient, AbbVie, Device, Novo Nordisk, Sanofi, Ionis Pharmaceuticals, Johnson & Johnson, Therapy, Conference, Takeda Pharmaceutical Company, Pharmaceutical industry, Medical device, Genentech, Pfizer

NEW YORK, July 12, 2023 /PRNewswire-PRWeb/ -- The Conference Forum announced the 13th annual PODD: Partnership Opportunities in Drug Delivery conference will take place October 16-17 at the Westin Copley Place, in Boston, MA.

Key Points: 
  • The Conference Forum announced the 13th annual PODD Drug Delivery Conference's 2023 keynotes and plenary sessions.
  • NEW YORK, July 12, 2023 /PRNewswire-PRWeb/ -- The Conference Forum announced the 13th annual PODD: Partnership Opportunities in Drug Delivery conference will take place October 16-17 at the Westin Copley Place, in Boston, MA.
  • "PODD is the most comprehensive industrial drug delivery partnering conference annually held in Boston," said Vincent Ling, Senior Director, Center for External Innovation at Takeda.
  • The PODD 2023 keynotes and featured speakers include:
    MIT's Dr Robert Langer, a pioneer in the research and development of drug delivery technology, will discuss the state of innovation in the drug delivery industry.

ExchangeRight REIT Completes 506(c) Conversion Following Successful Public Reporting Launch

Retrieved on: 
Wednesday, July 12, 2023
Kroger, Hobby Lobby, Uncertainty, Fresenius Medical Care, Essential, Walgreens, Walmart, Sponsor, REIT, COVID-19, CVS, COVID, Medicare, DST, Investment, Collection, Risk, Tractor Supply Company, Growth, Takeda Pharmaceutical Company, Real estate, Security (finance)

94.19% of the portfolio's annualized base rent is generated from essential businesses.

Key Points: 
  • 94.19% of the portfolio's annualized base rent is generated from essential businesses.
  • The REIT's fully identified portfolio is diversified across 943 properties, 627 markets, 16+ million square feet, 43 states, and 55 recession-resilient tenants across 16 necessity-based industries.
  • Warren Thomas, a managing partner at ExchangeRight, shared the story of the Essential Income REIT's uniquely strong track record and the investment strategy behind it.
  • Joshua Ungerecht, a managing partner at ExchangeRight, cited the Essential Income REIT's strong performance as a key reason for the offering's net inflows of investor capital.

Next-Generation Sequencing Informatics Market Projected to Achieve US$ 3.2 Billion, Registering a CAGR of 19.40%

Retrieved on: 
Tuesday, July 11, 2023
Cloud, Informatics, DNA, Centre for Arab Genomic Studies, Drug discovery, Classification, Hospital, NGS, Overalls, Generator, Infection, Personalized medicine, Test automation management tools, Cloud computing, ML, Biophysical environment, Research, Genomics, RNA, DSM-IV codes, National Institute for Research Advancement, Environmental monitoring, USD, National Computational Infrastructure, Organization, Data analysis, Application, Machine learning, Algorithm, Medicine, Artificial intelligence, Agriculture, Diagnosis, Ortho Clinical Diagnostics, Test management, Takeda Pharmaceutical Company, Massive parallel sequencing, Software, Medical device, Nursing, Pharmaceutical industry, Vaccine, Construction

Improved healthcare infrastructure and increasing awareness regarding the next-generation sequencing has become a leading factor in market growth.

Key Points: 
  • Improved healthcare infrastructure and increasing awareness regarding the next-generation sequencing has become a leading factor in market growth.
  • What are new technologies and trends in Next-Generation Sequencing Informatics Market?
  • Artificial intelligence (AI) and machine learning (ML) have a transformative impact on Next-Generation Sequencing (NGS) Informatics.
  • Download the PDF Brochure Report:
    Key Reasons to Purchase the Report:
    The Next-Generation Sequencing (NGS) Informatics Market offers significant opportunities for genomics research and precision medicine.

Next-Generation Sequencing Informatics Market Projected to Achieve US$ 3.2 Billion, Registering a CAGR of 19.40%

Retrieved on: 
Tuesday, July 11, 2023
Cloud, Informatics, DNA, Centre for Arab Genomic Studies, Drug discovery, Classification, Hospital, NGS, Overalls, Generator, Infection, Personalized medicine, Test automation management tools, Cloud computing, ML, Biophysical environment, Research, Genomics, RNA, DSM-IV codes, National Institute for Research Advancement, Environmental monitoring, USD, National Computational Infrastructure, Organization, Data analysis, Application, Machine learning, Algorithm, Medicine, Artificial intelligence, Agriculture, Diagnosis, Ortho Clinical Diagnostics, Test management, Takeda Pharmaceutical Company, Massive parallel sequencing, Software, Medical device, Nursing, Pharmaceutical industry, Vaccine, Construction

Improved healthcare infrastructure and increasing awareness regarding the next-generation sequencing has become a leading factor in market growth.

Key Points: 
  • Improved healthcare infrastructure and increasing awareness regarding the next-generation sequencing has become a leading factor in market growth.
  • What are new technologies and trends in Next-Generation Sequencing Informatics Market?
  • Artificial intelligence (AI) and machine learning (ML) have a transformative impact on Next-Generation Sequencing (NGS) Informatics.
  • Download the PDF Brochure Report:
    Key Reasons to Purchase the Report:
    The Next-Generation Sequencing (NGS) Informatics Market offers significant opportunities for genomics research and precision medicine.

Armis Named Leader in GigaOm Radar Report for Operational Technology (OT) Security

Retrieved on: 
Monday, July 10, 2023
Data Management, Security, Technology, Software, Artificial Intelligence, Internet, Hardware, OT, Radar, PLC, Operational technology, ISO, Innovation, SOC, IDS, Colgate-Palmolive, Public sector, Plant, Gigaom, Cross-platform play, Safety, Takeda Pharmaceutical Company, Risk management, Instrumentation, Medical device, United States Army Command, Control, Communication, Computers, Cyber, Intelligence, Surveillance and Reconnaissance Center

Armis , the leading asset visibility and security company, today announced that it has been named a leader in the GigaOm Radar Report for Operational Technology (OT) Security .

Key Points: 
  • Armis , the leading asset visibility and security company, today announced that it has been named a leader in the GigaOm Radar Report for Operational Technology (OT) Security .
  • “We’re proud to be recognized by GigaOm as a leader in operational technology security,” said Nadir Izrael, CTO and Co-founder, Armis.
  • All these factors made it easy to choose Armis, frankly,” said Mike Towers, Chief Security and Trust Officer, Takeda Pharmaceuticals.
  • As our leadership continues to collaborate with Armis leadership, we can create these unique use cases that provide tremendous benefits for specific teams or individuals.”
    To read the full GigaOm Radar Report for Operational Technology (OT) Security, please visit: https://www.armis.com/analyst-reports/gigaom-radar-for-ot-security/
    For the Armis blog surrounding this report, go to: https://www.armis.com/blog/armis-named-leader-in-gigaom-radar-report-for...
    Learn more about Armis’ OT cybersecurity solutions and how the company is helping customers secure operational technology here: https://www.armis.com/solutions/ot-device-security/

Everest Group Publishes 2023 Rating of Top Global Business Services Employers

Retrieved on: 
Thursday, July 6, 2023
JPMorgan Chase, AT&T, GSK, Heart, International, Cisco, AT, Henkel, Philip Morris International, Motorola Solutions, Perception, Expedia Group, Diageo, Top, Research, Ford Motor Company, AstraZeneca, Colgate-Palmolive, Organization, Sun Life Financial, Synchrony Financial, Bank of America, Procter & Gamble, Macquarie Group, RELX, IBM Consulting, Amazon (company), Patient, Chart, GBS, Growth, Johnson & Johnson, Avon Products, Ecosystem, Bank, Takeda Pharmaceutical Company, Wells Fargo, ING Group, Sales, Creative industries, Sintering, Accounting, Colt, Northern Trust, Experian, American Express, Mars, Target, Bayer

DALLAS, July 6, 2023 /PRNewswire-PRWeb/ -- Everest Group today released the results of its second annual rating of top Global Business Services (GBS) employers across India, the Philippines and Poland. The Everest Group Top GBS Employers™ report for 2023 provides an "outside-in proxy" on how prospective candidates perceive employer companies. Leading global GBS organizations can leverage insights from this study to optimize their talent management strategies.

Key Points: 
  • DALLAS, July 6, 2023 /PRNewswire-PRWeb/ -- Everest Group today released the results of its second annual rating of top Global Business Services (GBS) employers across India, the Philippines and Poland.
  • The Everest Group Top GBS Employers™ report for 2023 provides an "outside-in proxy" on how prospective candidates perceive employer companies.
  • For this year's study, Everest Group analyzed the employer brand perception of more than 300 leading GBS employers across India, the Philippines and Poland.
  • Among 165 India-based companies assessed by Everest Group, 30 employers were designated the Top GBS Employers in India.

Unlocking the True Potential of AI with Automation: UiPath Reveals Expanded Generative AI and Specialized AI Offerings

Retrieved on: 
Tuesday, June 27, 2023
Apps, Applications, Technology, Finance, Fintech, Professional Services, Software, Electronic Design Automation, Robotics, Data Management, Artificial Intelligence, Classification, GPT, LLM, NatWest Group, Communication, Synthetic media, Intelligent automation, Intelligence, OpenAI, Automation, McKinsey & Company, Document, Generalization, Palm, Generative, Specialization, AI, NYSE, AWS, Mining, Takeda Pharmaceutical Company, Customer service, Sales, Medical device, British Airways, UiPath, So Special (Ai and Atsushi song)

The UiPath Business Automation Platform is adding more AI offerings with Generative AI, including the general availability of OpenAI and Azure OpenAI connectors with support for GPT-4.

Key Points: 
  • The UiPath Business Automation Platform is adding more AI offerings with Generative AI, including the general availability of OpenAI and Azure OpenAI connectors with support for GPT-4.
  • UiPath customers are already using the OpenAI connector to extend automation deeper into business operations and turn data into actionable insights.
  • UiPath is continuing to make significant advancements in Specialized AI, refining its industry-leading solutions such as Document Understanding and Communications Mining by incorporating GPT-based technologies.
  • “AI technologies are at the core of the UiPath Business Automation Platform, and we are excited to extend the capabilities of our enterprise automation with new Generative AI and Specialized AI offerings,” said Graham Sheldon, Chief Product Officer at UiPath.

Apogee Therapeutics Strengthens Team with Appointments of Industry Leaders to Board of Directors and Management

Retrieved on: 
Thursday, June 22, 2023
Health, Infectious Diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Jennifer Fox, Bear Stearns, Migraine, Depression, Biochemistry, Diabetes, Doctor of Philosophy, Marketing, Schizophrenia, Elizabeth Glaser Pediatric AIDS Foundation, Texas A&M University, Biogen, CMC, Atrial fibrillation, ODT, Business, Atopic dermatitis, MBA, MIT, Merck & Co., Bristol Myers Squibb, Deutsche Bank, AstraZeneca, Prudential Securities, Chronic obstructive pulmonary disease, Chemistry, Organization, Neuroscience, Bank of America, CDMO, Bowdoin College, Citigroup, Engineering, Boehringer Ingelheim, CFO, Merck, United States Department of the Air Force, Bank, Stanford Graduate School of Business, Therapy, Nitrome, Bipolar, Pfizer, Takeda Pharmaceutical Company, Pharmaceutical industry, Management, Manhattan College, Apsis

Additionally, Apogee announced the appointment of Rebecca Dabora, Ph.D., an expert in chemistry, manufacturing and controls (CMC), as chief technology officer.

Key Points: 
  • Additionally, Apogee announced the appointment of Rebecca Dabora, Ph.D., an expert in chemistry, manufacturing and controls (CMC), as chief technology officer.
  • “We are thrilled to further strengthen the Apogee team with the appointments of both Jennifer and BJ to our board of directors and Becky to our senior management team, and to leverage their respective expertise in the industry,” said Michael Henderson, M.D., chief executive officer of Apogee.
  • Ms. Fox currently serves on the board of directors and as chair of the audit committee of ProKidney Corp. and on the board of directors of Life Science Cares.
  • Dr. Dabora has served in executive roles leading the technical operations function for several companies, including Invivyd, Aspyrian Therapeutics, SwanBio Therapeutics and others.

Accumulus Synergy Appoints Jacques Mascaro as Chair of the Board

Retrieved on: 
Thursday, June 22, 2023
RAPS, Heart, Chairperson, Senior, Chair, Doctor of Philosophy, ESMO, COVID-19, MBA, AstraZeneca, Science, ASCO, Research and development, Development, Patient, Ecosystem, Research, DIA, Takeda Pharmaceutical Company, Pharmaceutical industry

BURLINGAME, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Accumulus Synergy (“Accumulus”), a nonprofit trade association working to address the global need for digital transformation within the life sciences - regulatory ecosystem, today announced the appointment of Jacques Mascaro as the new Chair of the Board of Directors (the “Board”).

Key Points: 
  • BURLINGAME, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Accumulus Synergy (“Accumulus”), a nonprofit trade association working to address the global need for digital transformation within the life sciences - regulatory ecosystem, today announced the appointment of Jacques Mascaro as the new Chair of the Board of Directors (the “Board”).
  • Jacques Mascaro, Ph.D., MBA, Senior Vice President, Global Head of Oncology Regulatory Science, Strategy & Excellence at AstraZeneca, brings a wealth of experience and leadership expertise to the role.
  • In his new role as Chair of the Board, Dr. Mascaro will work closely with the other Directors and members of the Accumulus Executive Leadership Team to ensure the continued success of the organization.
  • I look forward to working with Jacques in this new capacity, along with the entire Board, to democratize the Accumulus Platform and achieve digital transformation.”
    Dr. Mascaro said, “I am honored to take on the role of Chair of the Board for Accumulus.

HepQuant Announces Additions to the Executive Leadership Team to Drive Commercialization

Retrieved on: 
Tuesday, June 13, 2023
Pharmaceutical, Health, Medical Devices, Intellectual property, Diagnosis, Senior, Hepatology, Marketing, Liver disease, Biotechnology, Policy, MBA, Medicine, Biomarker, Strategic planning, Doctor of Philosophy, Organization, Takeda Pharmaceutical Company, DSM-IV codes, Acquisition, MD, Patient, Risk, Nursing care plan, R, Neurology, Management, Takeda, Veloxis Pharmaceuticals

HepQuant, LLC, a leader transforming the management of liver diseases, announces key additions to its executive leadership team.

Key Points: 
  • HepQuant, LLC, a leader transforming the management of liver diseases, announces key additions to its executive leadership team.
  • Four seasoned executives have joined HepQuant to round out the Company’s leadership team and finalize preparations to launch its quantitative liver function test.
  • Dr. Pitts joins HepQuant with more than 20 years of business, R&D and operational leadership experience in biotechnology, biopharma, and medical diagnostics.
  • She is a diagnostics industry executive with deep experience in strategic marketing, cross-functional team management, commercialization and reimbursement strategy.